Tucker Asset Management LLC Has $270,000 Holdings in Bristol-Myers Squibb (NYSE:BMY)

Tucker Asset Management LLC grew its stake in Bristol-Myers Squibb (NYSE:BMY) by 3,313.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,779 shares of the biopharmaceutical company’s stock after purchasing an additional 4,639 shares during the quarter. Tucker Asset Management LLC’s holdings in Bristol-Myers Squibb were worth $270,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of BMY. Intrust Bank NA increased its stake in shares of Bristol-Myers Squibb by 38.8% during the fourth quarter. Intrust Bank NA now owns 31,791 shares of the biopharmaceutical company’s stock worth $1,798,000 after purchasing an additional 8,894 shares during the period. Biondo Investment Advisors LLC lifted its holdings in shares of Bristol-Myers Squibb by 0.9% during the fourth quarter. Biondo Investment Advisors LLC now owns 142,200 shares of the biopharmaceutical company’s stock worth $8,043,000 after buying an additional 1,260 shares in the last quarter. Allstate Corp bought a new position in Bristol-Myers Squibb during the fourth quarter worth about $3,411,000. DnB Asset Management AS raised its stake in Bristol-Myers Squibb by 47.2% in the 4th quarter. DnB Asset Management AS now owns 709,131 shares of the biopharmaceutical company’s stock worth $40,108,000 after purchasing an additional 227,521 shares in the last quarter. Finally, denkapparat Operations GmbH bought a new stake in Bristol-Myers Squibb in the 4th quarter valued at about $834,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

BMY has been the topic of a number of analyst reports. Bank of America reissued a “neutral” rating and set a $63.00 price target on shares of Bristol-Myers Squibb in a research report on Tuesday, December 10th. Jefferies Financial Group raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and lifted their price objective for the company from $63.00 to $70.00 in a research note on Monday, December 16th. Citigroup boosted their target price on Bristol-Myers Squibb from $60.00 to $65.00 and gave the stock a “neutral” rating in a research note on Tuesday, January 28th. Wells Fargo & Company lifted their price target on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an “equal weight” rating in a report on Friday, February 7th. Finally, Cantor Fitzgerald boosted their price target on Bristol-Myers Squibb from $50.00 to $55.00 and gave the stock a “neutral” rating in a report on Tuesday, February 4th. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating, four have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $57.86.

Bristol-Myers Squibb Stock Performance

NYSE BMY opened at $60.10 on Friday. The company has a fifty day moving average price of $58.55 and a 200-day moving average price of $56.25. The firm has a market cap of $121.96 billion, a price-to-earnings ratio of -13.60, a PEG ratio of 2.07 and a beta of 0.43. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15. Bristol-Myers Squibb has a 1 year low of $39.35 and a 1 year high of $63.33.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, February 6th. The biopharmaceutical company reported $1.67 EPS for the quarter, beating the consensus estimate of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. As a group, equities research analysts predict that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, May 1st. Stockholders of record on Friday, April 4th will be given a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a dividend yield of 4.13%. The ex-dividend date of this dividend is Friday, April 4th. Bristol-Myers Squibb’s dividend payout ratio is presently -56.11%.

Insider Transactions at Bristol-Myers Squibb

In other news, EVP Samit Hirawat bought 1,823 shares of the stock in a transaction on Friday, February 14th. The shares were purchased at an average cost of $54.84 per share, for a total transaction of $99,973.32. Following the completion of the purchase, the executive vice president now directly owns 63,932 shares in the company, valued at $3,506,030.88. This represents a 2.94 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.09% of the company’s stock.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.